PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Detecting cancer cells in blood can give an early warning of treatment failure

2015-03-23
(Press-News.org) A blood test that measures the number of cells shed from prostate tumours into the bloodstream can act as an early warning sign that treatment is not working, a major new study shows.

Researchers showed that measuring the numbers of circulating tumour cells in the blood predicted which men were benefitting least from a prostate cancer drug after as little as 12 weeks of treatment.

They hope their work will allow doctors to switch patients to alternative treatments earlier than is currently possible, if these results are confirmed by further studies. The research could also hasten the development of cancer treatments by speeding up clinical trials, since doctors could tell much earlier whether a treatment is working.

The study was led in the UK by researchers at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, and also involved several leading international institutions.

It was funded by a range of organisations including a Medical Research Council biomarkers grant, the companies Janssen Diagnostics, the Prostate Cancer Foundation in the US, and Prostate Cancer UK.

As tumours grow and progress, they shed cancer cells into the bloodstream, some of which can seed new secondary tumours elsewhere in the body. So the researchers wanted to see whether a high number of circulating tumours cells was an indication of a growing tumour that wasn't responding to treatment, and could predict a lower chance of survival.

The study, published in the Journal of Clinical Oncology today (Monday), involved the detailed analysis of blood samples from 711 men who took part in a major phase III trial of the prostate cancer drug abiraterone.

Researchers measured numbers of circulating tumour cells at four-week periods after the start of treatment with the drug, along with a range of other biomarker molecules in the blood including lactate dehydrogenase (LDH), high levels of which are a sign of general tissue damage.

The trial itself had used the standard trial end points of average overall survival and survival free of cancer progression to show abiraterone's effectiveness in late-stage prostate cancer. But the researchers were able to cross-reference those results with data on circulating tumour cells and LDH levels in each man taking part.

They found a correlation between those men who had responded least well to treatment with abiraterone, and higher levels of cancer cells and LDH in the bloodstream, measured 12 weeks after starting treatment. They showed that levels of circulating tumour cells varied independently of a range of other biomarkers.

To prove the effectiveness of a new drug, clinical trials normally need to be run until the cancer is progressing clinically for each patient - and often until many of the patients on the trial have died. But with this new blood test, it might be possible to use circulating tumour cells as an early indicator that a drug is or is not working, and as a predictor of survival.

Study leader Professor Johann de Bono, Professor of Experimental Cancer Therapeutics at The Institute of Cancer Research, London, and Honorary Consultant at The Royal Marsden NHS Foundation Trust, said:

"The past decade has seen unprecedented success in the development of new drugs for advanced, metastatic prostate cancer. One of the major challenges we face now is in optimising the use of these new treatments by making sure that the right men receive them, and only for as long as they are benefitting.

"Our study showed that circulating tumour cells act as an early warning test for men who are not responding to treatment - potentially allowing doctors to switch patients early to alternative options. We hope our results will not only lead to better use of the current range of treatments, but also speed up the discovery of new drugs by providing an important new tool to the researchers trialling them."

Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:

"Using a blood test to assess whether a cancer drug is working would be much easier and more convenient than other methods of monitoring treatment, and might pick up signs that a tumour is not responding weeks or months earlier than is achievable now. It could give doctors a valuable early warning that treatment is not working, and an opportunity to switch the patient promptly to an alternative drug."

INFORMATION:

Notes to editors For more information contact Claire Hastings, Media Officer at ICR, on 020 7153 5380 / chastings@icr.ac.uk. For enquiries out of hours, please call 07595963613.

The Institute of Cancer Research, London, is one of the world's most influential cancer research institutes.

Scientists and clinicians at The Institute of Cancer Research (ICR) are working every day to make a real impact on cancer patients' lives. Through its unique partnership with The Royal Marsden NHS Foundation Trust and 'bench-to-bedside' approach, the ICR is able to create and deliver results in a way that other institutions cannot. Together the two organisations are rated in the top four cancer centres globally.

The ICR has an outstanding record of achievement dating back more than 100 years. It provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today it leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment.

As a college of the University of London, the ICR provides postgraduate higher education of international distinction. It has charitable status and relies on support from partner organisations, charities and the general public.

The Royal Marsden NHS Foundation Trust

The Royal Marsden opened its doors in 1851 as the world's first hospital dedicated to cancer diagnosis, treatment, research and education. Today, together with its academic partner, The Institute of Cancer Research (ICR), it is the largest and most comprehensive cancer centre in Europe treating over 50,000 NHS and private patients every year. It is a centre of excellence with an international reputation for groundbreaking research and pioneering the very latest in cancer treatments and technologies.

The Royal Marsden, with the ICR, is the only National Institute for Health Research Biomedical Research Centre for Cancer. First awarded the status in 2006, it was re-awarded in 2011. A total of £62 million is being provided over five years, to support pioneering research work, and is being shared out over eight different cancer themes. The Royal Marsden also provides community services in the London boroughs of Sutton and Merton and in June 2010, along with the ICR, the Trust launched a new academic partnership with Mount Vernon Cancer Centre in Middlesex.

Since 2004, the hospital's charity, The Royal Marsden Cancer Charity, has helped raise over £100 million to build theatres, diagnostic centres, and drug development units.

Prince William became President of The Royal Marsden in 2007, following a long royal connection with the hospital.



ELSE PRESS RELEASES FROM THIS DATE:

Insulin resistance linked to a human gene variant

2015-03-23
Insulin resistance is a risk factor for developing both type 2 diabetes and cardiovascular disease. Almost one third of the U.S. population has some degree of insulin resistance, though it is undiagnosed in many of these individuals. Obesity is associated with reduced insulin sensitivity and the development of insulin resistance. However, recent large-scale genetic studies have indicated that insulin resistance is heritable. A new study in the Journal of Clinical Investigation identifies a gene that is strongly associated with the presence of many features of insulin resistance. ...

Metabolic compensation underlies drug resistance in glioblastoma

2015-03-23
Gliobststoma (GBM) is a highly aggressive brain tumor that is resistant to many conventional cancer therapies. The kinase mTOR induces pathways that are aberrantly activated in GBM. However, mTOR inhibitors have not shown much promise for treating GBM. A new study in the Journal of Clinical Investigation indicates that mTOR inhibitor resistance in GBM is likely the result of compensatory glutamine metabolism. Kazuhiro Tanaka and colleagues at Kobe University determined that glutaminase and glutamine levels increase in GBM cells and xenografts in response to mTOR inhibition. ...

Greater wealth equals better health for most Canadian moms and their newborns

2015-03-23
TORONTO, March 23, 2015 -- Across all income levels, Canadian moms in better socioeconomic standing have better health outcomes than moms in lower socioeconomic brackets. The same relationship between socioeconomic position and health outcomes holds true for these moms' newborn babies, according to a new study. A team of researchers placed 68,705 Canadian new moms and their babies along a socioeconomic spectrum by using factors about the moms such as education, whether she was living in poverty and the income of the neighbourhood she lives in. The researchers compared ...

How to get smarter on pills for seniors

2015-03-23
(PHILADELPHIA) - Open the medicine cabinet of a senior and you're likely to find scores of pill bottles. Physicians are often unaware of all the medications a patient is taking, which can result in unnecessary additional prescriptions, non-prescription medications and potential drug-drug interactions that cause unexpected adverse effects. When a cancer diagnosis is thrown into the mix, the drug-drug interactions can become even more complex. A new study evaluates the currently available screening tools for determining if and when seniors with cancer are taking too many ...

Unraveling cystic fibrosis puzzle, taking it personally matters

2015-03-23
In the genetic disorder cystic fibrosis (CF), the most severe symptoms are recurring episodes of lung inflammation and bacterial infection (known as "exacerbations") that happen from one to three times a year and cause ever-increasing amounts of lung damage through the course of a CF patient's life. While it is well understood that CF lung problems are ultimately due to bacterial infections encouraged by a CF patient's abnormally thick mucus, medical science has been unable to define specific causes that trigger the periodic flare-ups. In a recent article in the Journal ...

Global water use may outstrip supply by mid-century

2015-03-23
DURHAM, N.C. -- Population growth could cause global demand for water to outpace supply by mid-century if current levels of consumption continue. But it wouldn't be the first time this has happened, a Duke University study finds. Using a delayed-feedback mathematical model that analyzes historic data to help project future trends, the researchers identified a regularly recurring pattern of global water use in recent centuries. Periods of increased demand for water -- often coinciding with population growth or other major demographic and social changes -- were followed ...

Report reveals alarming lack of water, sanitation and hygiene in health care facilities

2015-03-23
The World Health Organization and UNICEF have commissioned the first comprehensive, multi-country analysis on water, sanitation and hygiene (WaSH) services in health care facilities, calling for global action to push toward 100 percent coverage of these services through new policies, collaboration, monitoring and training. The report, released March 17, evaluated available WaSH data from 66,101 health-care facilities in 54 low- and middle-income countries and found that 38 percent of those facilities lack an improved water source, 19 percent lack improved sanitation, ...

Quantum cause and effect

2015-03-23
Does taking a drug and then getting better mean that the drug made you better? Did that tax cut really stimulate the economy or did it recover on its own? The problem of answering such questions - of inferring causal relationships from correlations - reaches across the sciences, and beyond. Normally, correlation by itself does not imply causation. But new research from Perimeter and the Institute for Quantum Computing (IQC) has found that in the case of quantum variables, it sometimes can. The new work, just published in Nature Physics, is the result of a collaboration ...

New insights into survival outcomes of Asian Americans diagnosed with cancer

2015-03-23
Numerous studies have documented racial differences in deaths from cancer among non-Hispanic whites and African Americans, but little has been known about survival outcomes for Asian Americans who have been diagnosed with cancer, until now. A new study from Quoc-Dien Trinh, MD and colleagues at Brigham and Women's Hospital (BWH) examined cancer patients in eight different Asian American subgroups and found their cancer-specific mortality (CSM) was substantially lower than that of non-Hispanic white patients. The findings are published in the March 20 issue of the Journal ...

Better debugger

2015-03-23
Integer overflows are one of the most common bugs in computer programs -- not only causing programs to crash but, even worse, potentially offering points of attack for malicious hackers. Computer scientists have devised a battery of techniques to identify them, but all have drawbacks. This month, at the Association for Computing Machinery's International Conference on Architectural Support for Programming Languages and Operating Systems, researchers from MIT's Computer Science and Artificial Intelligence Laboratory (CSAIL) will present a new algorithm for identifying ...

LAST 30 PRESS RELEASES:

Scientists unlock secrets behind flowering of the king of fruits

Texas A&M researchers illuminate the mysteries of icy ocean worlds

Prosthetic material could help reduce infections from intravenous catheters

Can the heart heal itself? New study says it can

Microscopic discovery in cancer cells could have a big impact

Rice researchers take ‘significant leap forward’ with quantum simulation of molecular electron transfer

Breakthrough new material brings affordable, sustainable future within grasp

How everyday activities inside your home can generate energy

Inequality weakens local governance and public satisfaction, study finds

Uncovering key molecular factors behind malaria’s deadliest strain

UC Davis researchers help decode the cause of aggressive breast cancer in women of color

Researchers discovered replication hubs for human norovirus

SNU researchers develop the world’s most sensitive flexible strain sensor

Tiny, wireless antennas use light to monitor cellular communication

Neutrality has played a pivotal, but under-examined, role in international relations, new research shows

Study reveals right whales live 130 years — or more

Researchers reveal how human eyelashes promote water drainage

Pollinators most vulnerable to rising global temperatures are flies, study shows

DFG to fund eight new research units

Modern AI systems have achieved Turing's vision, but not exactly how he hoped

Quantum walk computing unlocks new potential in quantum science and technology

Construction materials and household items are a part of a long-term carbon sink called the “technosphere”

First demonstration of quantum teleportation over busy Internet cables

Disparities and gaps in breast cancer screening for women ages 40 to 49

US tobacco 21 policies and potential mortality reductions by state

AI-driven approach reveals hidden hazards of chemical mixtures in rivers

Older age linked to increased complications after breast reconstruction

ESA and NASA satellites deliver first joint picture of Greenland Ice Sheet melting

Early detection model for pancreatic necrosis improves patient outcomes

Poor vascular health accelerates brain ageing

[Press-News.org] Detecting cancer cells in blood can give an early warning of treatment failure